Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.87 -1.8%	$0.88	$0.46 ▼ $7.49	$4.63M	-0.16	613,113 shs	4,276 shs
CGTX Cognition Therapeutics	$0.24 -5.8%	$0.37	$0.22 ▼ $2.54	$15.10M	1	2.61 million shs	1.62 million shs
ELEV Elevation Oncology	$0.30 -1.0%	$0.31	$0.22 ▼ $4.33	$17.92M	1.59	1.38 million shs	467,202 shs
MTEX Mannatech	$9.63 +1.1%	$9.77	$6.75 ▼ $16.49	$18.31M	1.06	4,437 shs	3,384 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	-1.81%	-3.94%	-11.61%	-13.40%	-82.14%
CGTX Cognition Therapeutics	-5.76%	-23.47%	-41.51%	-46.85%	-88.93%
ELEV Elevation Oncology	-0.98%	-4.54%	-15.03%	-41.27%	-92.10%
MTEX Mannatech	-0.89%	-8.47%	-14.79%	-16.20%	+25.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	1.8402 of 5 stars	0.0	5.0	3.6	1.7	0.6
CGTX Cognition Therapeutics	2.8469 of 5 stars	3.5	3.0	1.6	2.5	1.3
ELEV Elevation Oncology	2.6257 of 5 stars	4.2	2.0	1.9	1.7	0.6
MTEX Mannatech	0.7401 of 5 stars	0.0	4.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
CGTX Cognition Therapeutics	3.00	Buy	$5.63	2,209.11% Upside
ELEV Elevation Oncology	2.30	Hold	$3.39	1,019.24% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest APM, MTEX, ELEV, and CGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
3/24/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
3/24/2025	ELEV Elevation Oncology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
3/21/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2025	ELEV Elevation Oncology	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	ELEV Elevation Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $0.70
3/21/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $1.00
3/20/2025	ELEV Elevation Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	10.77	N/A	N/A	$2.97 per share	0.29
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.76 per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A
MTEX Mannatech	$115.04M	0.16	N/A	N/A	$5.64 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$2.83M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	-$25.79M	-$0.74	N/A	N/A	N/A	N/A	-150.93%	-100.82%	8/14/2025 (Estimated)
ELEV Elevation Oncology	-$45.70M	-$0.82	N/A	N/A	N/A	N/A	-59.73%	-40.05%	8/5/2025 (Estimated)
MTEX Mannatech	-$2.24M	-$0.10	N/A	∞	N/A	-1.26%	-15.62%	-3.76%	8/11/2025 (Estimated)

Latest APM, MTEX, ELEV, and CGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/13/2025	Q1 2025	MTEX Mannatech	N/A	-$0.80	N/A	-$0.80	N/A	$26.56 million
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
3/26/2025	Q4 2024	MTEX Mannatech	N/A	$1.20	N/A	$1.20	N/A	$29.01 million
3/20/2025	Q4 2024	CGTX Cognition Therapeutics	-$0.16	-$0.17	-$0.01	-$0.17	N/A	N/A
3/6/2025	Q4 2024	ELEV Elevation Oncology	-$0.22	-$0.18	+$0.04	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	$0.20	2.08%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	0.24	1.16	N/A
CGTX Cognition Therapeutics	N/A	2.11	2.11
ELEV Elevation Oncology	0.45	17.77	17.77
MTEX Mannatech	0.44	1.25	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CGTX Cognition Therapeutics	43.35%
ELEV Elevation Oncology	83.70%
MTEX Mannatech	12.98%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CGTX Cognition Therapeutics	20.75%
ELEV Elevation Oncology	8.10%
MTEX Mannatech	41.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.87 million	Not Optionable
CGTX Cognition Therapeutics	20	61.99 million	32.93 million	Not Optionable
ELEV Elevation Oncology	40	59.22 million	54.33 million	Optionable
MTEX Mannatech	250	1.90 million	1.10 million	Not Optionable

APM, MTEX, ELEV, and CGTX Headlines

Recent News About These Companies

Mannatech (NASDAQ:MTEX) Now Covered by Analysts at Wall Street Zen

May 23, 2025 | americanbankingnews.com

Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

May 21, 2025 | businesswire.com

Mannatech Reports Financial Results for First Quarter 2025

May 13, 2025 | businesswire.com

Astronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancements

April 14, 2025 | msn.com

Mannatech Reports Fourth Quarter 2024 Financial Results

March 26, 2025 | businesswire.com

Mannatech Stock Soars to 52-Week High, Hits $16 Mark

January 30, 2025 | msn.com

Mannatech names Robert Toth vice chairman of the board

November 27, 2024 | markets.businessinsider.com

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

November 26, 2024 | businesswire.com

Mannatech Inc. Q3 Earnings Summary

November 13, 2024 | markets.businessinsider.com

Mannatech Reports Financial Results for Third Quarter 2024

November 12, 2024 | businesswire.com

Trading (MTEX) With Integrated Risk Controls

October 17, 2024 | news.stocktradersdaily.com

(MTEX) Investment Analysis

October 6, 2024 | news.stocktradersdaily.com

Mannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in Stock

September 12, 2024 | insidertrades.com

Director Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)

September 11, 2024 | finance.yahoo.com

(MTEX) Trading Signals

August 19, 2024 | news.stocktradersdaily.com

Mannatech Reports Financial Results for Second Quarter 2024

August 13, 2024 | finance.yahoo.com

How To Trade (MTEX)

July 29, 2024 | news.stocktradersdaily.com

(MTEX) Long Term Investment Analysis

July 19, 2024 | news.stocktradersdaily.com

MTEX Stock Earnings: Mannatech Reported Results for Q1 2024

May 15, 2024 | investorplace.com

Mannatech Reports Financial Results for First Quarter 2024

May 14, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
By Chris Markoch | May 20, 2025
View CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
Recession Prep: Consumer Staples are Back
By Jeffrey Neal Johnson | May 5, 2025
View Recession Prep: Consumer Staples are Back
D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?
By Nathan Reiff | May 28, 2025
View D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?

APM, MTEX, ELEV, and CGTX Company Descriptions

Aptorum Group NASDAQ:APM

$0.87 -0.02 (-1.81%)

Closing price 05/28/2025 03:58 PM Eastern

Extended Trading

$0.86 0.00 (-0.12%)

As of 05/28/2025 04:44 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Cognition Therapeutics NASDAQ:CGTX

$0.24 -0.01 (-5.76%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.24 0.00 (-1.07%)

As of 05/28/2025 07:16 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Elevation Oncology NASDAQ:ELEV

$0.30 0.00 (-0.98%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.32 +0.02 (+6.12%)

As of 05/28/2025 07:57 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Mannatech NASDAQ:MTEX

$9.63 +0.11 (+1.14%)

Closing price 05/28/2025 03:50 PM Eastern

Extended Trading

$9.63 +0.00 (+0.01%)

As of 05/28/2025 04:04 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time